A 29-amino-acid fragment of endogenous GHRH that prompts your own pituitary to release growth hormone — with FDA approval dating back to 1997.
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary to trigger growth hormone (GH) secretion. Unlike synthetic HGH itself, sermorelin doesn't introduce exogenous GH — it prompts your own pituitary to produce it.
The compound is a 29-amino-acid fragment representing the biologically active portion of endogenous GHRH(1-44). It was FDA-approved in 1997 under the name Geref for treating GH deficiency in children, making it one of the few peptides in this category with significant clinical history.
Sermorelin stimulates your own GH production rather than replacing it. This means GH release stays within normal physiological feedback loops — a meaningful difference in how it behaves compared to exogenous HGH.
The pituitary gland contains somatotroph cells with GHRH receptors. When sermorelin binds these receptors, it activates the cAMP signaling pathway, increasing synthesis and release of GH into circulation.
GH then travels to the liver and other tissues, stimulating production of insulin-like growth factor 1 (IGF-1). IGF-1 is responsible for most of the downstream effects researchers associate with GH — tissue repair, lean mass support, fat metabolism, and sleep quality.
Critically, this entire cascade is subject to normal negative feedback. Elevated GH and IGF-1 signal back to the hypothalamus to reduce GHRH output, which is why sermorelin tends to produce more physiological GH patterns than direct HGH administration.
GH is released in pulses, not continuously — the largest occurs during deep sleep. Sermorelin amplifies these natural pulses rather than creating a flat, supraphysiological GH curve. Research subjects typically show peak GH response 20–40 minutes after subcutaneous injection.
The bulk of sermorelin research has focused on GH deficiency and age-related GH decline (somatopause). As endogenous GH secretion decreases significantly after age 30, sermorelin has been studied as a method to restore more youthful GH pulsatility without the risks associated with exogenous HGH.
Sermorelin has more clinical data behind it than most peptides in this category due to its FDA-approved status. The pediatric GH deficiency literature provides a foundation that pure research compounds lack.
| Factor | Sermorelin | Synthetic HGH |
|---|---|---|
| Mechanism | Stimulates endogenous GH | Replaces GH directly |
| Feedback loop | Preserved | Bypassed |
| GH pattern | Pulsatile (physiological) | Flat/supraphysiological |
| IGF-1 response | Moderate, natural | Direct, dose-dependent |
| Pituitary suppression risk | Low | Higher with long-term use |
| Clinical history | FDA-approved (1997) | FDA-approved (various) |
| Cost | Significantly lower | Higher |
COA-verified vendor pricing, promo codes, and reconstitution guide.
View Pricing → Dosage Calculator